Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

18
AQXP / Aquinox Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AQXP

18
AQXP / Aquinox Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AQXP

18
Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

2018-08-08 globenewswire
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, 2018.
4503 ALPMY ALPMF AQXP

18
AQXP / Aquinox Pharmaceuticals, Inc. / EcoR1 Capital, LLC - null (Passive Investment)

2018-07-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934
AQXP

18
AQXP / Aquinox Pharmaceuticals, Inc. / EcoR1 Capital, LLC - null (Passive Investment)

2018-07-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934
AQXP

29
Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session

2018-07-13 zacks - 2
Akorn, Inc. (AKRX - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $15.04–$18.58 in the past one-month time frame, showed a sharp increase yesterday. The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged.
AKRX AQXP SAM PSB

18
AQXP / Aquinox Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-07-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) AQUINOX PHARMACEUTICALS, INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03842B101 (CUSIP NUMBER) June 30, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
AQXP

20
AQXP / Aquinox Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-07-10 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) AQUINOX PHARMACEUTICALS, INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03842B101 (CUSIP NUMBER) June 30, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
AQXP

21
Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory

2018-07-10 zacks - 3
Aquinox Pharmaceuticals, Inc. (AQXP - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors, there is some hope when looking at AQXP given that, according to its RSI reading of 20.16, it is now in oversold territory.
AQXP

18
Aquinox Axes Half its Workforce after Phase III Failure of Lead Drug Rospitor

2018-07-10 genengnews
Two weeks after acknowledging the failure of its lead drug candidate Rospitor (AQX-1125) in a Phase III trial in patients with interstitial cystitis/bladder pain syndrome (IC/BPS), Aquinox Pharmaceuticals has eliminated half its workforce—30 employees—and shut down its U.S. offices in San Bruno, CA.
4503 ALPMY ALPMF AQXP

24
AQXP / Aquinox Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-09 sec.gov - 6
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AQXP

57
Biotech: Take It On The Run

2018-07-05 seekingalpha - 7
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

18
Aquinox Tumbles 82% On Failed Late-Stage Study, But Proof-Of-Concept Trial Might Right The Ship

2018-07-03 seekingalpha
Aquinox Pharmaceuticals tumbles on failure of its phase 3 study in treating patients with cystitis/bladder pain syndrome using rosiptor.
AQXP

22
Massive Biopharma Movers of the Past Week

2018-06-30 247wallst - 2
Even though the markets are in the summer doldrums, the health care sector has been incredibly active. In fact, a few biopharma stocks made massive runs over the course of this past week, some losing more than half their cap. Although not all these moves were negative, the overall sentiment was negative.
ACHV SUMM CARA AQXP SMMT PTIE

488
Your Daily Pharma Scoop: FDA Approval For Array, Edge Zooms, Summit Nosedives

2018-06-29 seekingalpha - 3
Discussion: Array Biopharma’s (ARRY) combo treatment of encorafenib and binimetinib for patients with advanced melanoma associated with a BRAF mutation receives FDA approval. However, stocks are marginally down by -3.97% at yesterday’s closing of market. However, over the last 52-wk the stock price has risen almost at a steady rate from its 52-wk low of $7.15 to almost treble to June 20 peak of $20.
OMER JAZZ AMGN AZN AZN SUMM EDGE RTTR SMMT AQXP ARRY GALT

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 03842B101